Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
3% down today in a strongly rising market? Prelims out on 12 October. Hmmm. Something leaked maybe....
Prelims for year to 30th June 2015 are due 12th October http://www.investegate.co.uk/tristel-plc--tstl-/rns/notice-of-results/201509180700074373Z/ and from trading update to 21st May - The Company has raised its internal expectations for the current financial year, and pre-tax profit (before share-based payments) is now expected to be not less than £2.5m (2014: £1.8m) Paul Swinney, Chief Executive, comments "The sales momentum that has built within the business over the course of the past two and a half years is being maintained. Our cost base is well controlled and the organisation is dealing well with the execution of our growth strategy. All of this translates to a record profit to be reported for the year". http://www.investegate.co.uk/tristel-plc--tstl-/rns/trading-update/201505210700108045N/ Good dividend - Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products declares a special dividend of three pence per share payable on 6 August 2015 to shareholders on the register on 26 June 2015. The corresponding ex-dividend date is 25 June 2015. The Company expects to declare a final dividend for the year at the time of the preliminary results which are expected to be announced on 12 October 2015. http://www.investegate.co.uk/tristel-plc--tstl-/rns/special-dividend-and-notice-of-results/201506180700104436Q/
Hi, If you would like to hear by Paul Swinney, Chief Executive and Liz Dixon, Finance Director present Tristel's results and have the opportunity to ask them questions please register here: https://attendee.gotowebinar.com/register/4181164913402080769 Thanks, The Equity Development team
he NHS accounts for a quarter of Tristel's revenues and, with MRSA and Clostridium difficile affecting one in every 16 patients in NHS hospitals, demand is well underpinned. International growth is proving robust too: underlying sales from human health products overseas jumped by a fifth in the first half alone. I expect the company to report a continuation of this positive trend in next month's full-year results. So with Tristel's operational performance supported by both domestic and international growth, and the company forecast to grow EPS by a further 20 per cent in the current financial year, I feel that a cash adjusted PE ratio of 17 is more than warranted. Trading on a bid-offer spread of 91p to 95p, I would continue to run your very healthy profits.
Shares in Aim-traded Tristel (TSTL:95p), a maker of infection prevention, contamination-control and hygiene products, came within a penny of hitting my upgraded target price of 110p in early July, so it's hardly a surprise that price has come off the boil slightly. I first advised buying the shares at 60p ('Clean up on superbugs', 6 May 2014), subsequently updated the investment case at 80p ('Riding bumper profits', 26 February 2015) and last recommended running profits at 92p in June ('Blue sky potential', 10 June 2015). Since my last article was published the company has paid out a special dividend of 3p a share. However, with Tristel set to report record results for the fifth consecutive six month period when it releases its full-year results on Monday, 12 October, buoyed by strong profit contributions from direct sales operations in the UK, Germany and Australasia, I feel that there is scope for the share price to return to those summer highs. Ahead of the figures, analysts Paul Hill and Hannah Crowe at research firm Equity Development are pencilling in full-year revenues of £15.5m, implying 15 per cent like-for-like sales growth in the 12 months to end June 2015, and an operating margin in excess of 16 per cent, a 2.6 percentage point hike on the previous financial year. If achieved, this would result in pre-tax profits (before share-based payments) of at least £2.5m, or 38 per cent more than the £1.8m of profits reported in fiscal 2014. The business is highly cash generative too. Net funds are forecast to have risen by £1.1m to £3.7m in the 12-months to end June 2015 which covers the vast majority of the £1.25m cost of the special dividend. Expect a 37 per cent hike in the normal dividend to 2.2p too. Post the special payout, net cash on the balance sheet is the equivalent of almost 6p a share. Strong growth profile And there is no reason at all to expect the growth to end here either. Indeed, chairman Francisco Soler notes that his company has "a more exciting pipeline of new product developments than I have seen at any time in our corporate history. At the same time we are moving forward with regulatory approvals in new, game-changing markets." Reflecting this positive outlook, analysts at Equity Development predict revenues will rise by a further 15 per cent in the current financial year to £17.8m to drive up pre-tax profits up by a fifth to £3m. On this basis, expect EPS of 5.2p and another hike in the payout to 2.6p a share. Key to maintaining this double-digit sales growth rate is Tristel's high-margin and patented chlorine dioxide technology healthcare products, accounting for 85 per cent of sales. Prospects are rock solid. For instance, the company's best in class clinically proven consumables product, Tristel Wipes, is the most widely used decontamination method in ear, nose and throat, cardiology and ultrasound departments of UK hospitals. The NHS accounts for a quarter o
Surprised to see this marked down so far today. Great little company in my view with good potential. I see the chairman moved 25% of the equity into an international merchant bank 2 days ago, but still his family has beneficial ownership of that stake. Maybe mm's nervous that he may drip sell when market strengthens. But surely it could be a prelude to a bid. Looks like more upside than downside so I am thinking of doubling up. All views welcome!!
have been trying to hold this down but it is heading back to 110p due to the strength of buying. Someone paid a premium at 106p for a decent 20k of shares but the ask has remained at 105p. Looking forward to this powering ahead now.
in a soggy market. Will power ahead when sentiment is better in the overall picture. Nice to see Tristel prove a good defensive share with a dividend to boot.
can see this maybe going beyond previous year high now dyor
hi mate yep can see it being hit although I think maybe not so soon, maybe next year with increased revenues/profits but certainly is very telling for them take options at 134p! such a difference compared to most other AIM companies and BODs of other AIM companies!
HI Shan, I like the sound of that! Liz Dixon was given options at 63p in the event of sale of the company when the SP was 56p or thereabouts. And of course it has shot up materially since then. Therefore I think the below target would be arrived at in the expectation that we can reach it. Excellent!
Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces today that Paul Swinney, CEO and Elizabeth Dixon, Finance Director, have been granted options over 636,567 ordinary 1 pence shares ("Ordinary Shares") under the Tristel plc Performance Share Plan 2015. The options are exercisable at 1 pence per share subject to certain profit objectives being met or the share price of the Company being equal to or greater than 134 pence per Ordinary Share for a period of 30 consecutive dealing days. The options are exercisable for a period of five years from date of vesting in three equal tranches following publication of the annual results. The first tranche will vest, if performance conditions are met, on publication of the results to 30 June 2016.
Bullish on this stock & expect a further re-rate. http://www.fool.co.uk/investing/2015/06/22/3-aim-stocks-for-the-next-20-years-asos-plc-tristel-plc-omg-plc/
Bonus special dividend should give the SP a little kick-up today.
A study by Cardiff University published in American Journal of Infection Control, anyone see this today? Bodes well for Tristel
I think Simon's run profits tip has been the signal for people to profit take. I don't think he has raised his target to 110p, it is Equity Development’s target.
205k new shares issued for share options incorporated today, and suspect selling action of these created the opportunity - I certainly took the chance to grab another big chunk at below 85p, and look like others have done too. Nice !
which is a massive buying opportunity in my book. Must be just some profit taking as we know the company is doing well.
is the new floor. Seems 100p was resistance that could not be breached. We might tread water for a bit but I am sure this is going back to 100p
Profit taking as this has moved a fair bit over the past 2 weeks.
Is that why the sp has dropped 5% today?
Simon raises his target price to 110. http://www.investorschronicle.co.uk/2015/06/02/comment/simon-thompson/hitting-target-prices-GnO28Ac2eqovUnvH4hidnJ/article.html
Hi Jolly I am looking for 104p here. My target before the update was 90p but I am revising this upwards in the light of the recent update. There will also be a return of cash later this year as there are no real acquisitions to be made in the sector. Some of that cash pile is bound to be returned.
Just over ten months into its financial year and Tristel (TSTL) chief executive Paul Swinney is already certain the group will report record profits of at least £2.5m. The disinfectant product provider’s growth strategy to at least double 2014 revenues of £13.5m in three years is on track. In a trading update, Tristel said sales had been particularly strong in the UK, Germany and Australasia, with Russia the only region to disappoint. Analysts at Equity Development have upgraded their underlying pre-tax profit and earnings per share forecasts for 2016 to £2.5m and 4.36p respectively. IC View: This trading update has set last month’s tip (73.5p, 23 April) off to a flyer, and, at 85p the shares are already up 16 per cent. The PEG ratio is still below one, and at 19 times this year’s forecast earnings – falling to 16 times in 2016 – the shares continue to look attractive. Buy.